Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022 01:01 ET
|
Celyad Oncology SA
Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1...
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
September 20, 2022 01:00 ET
|
Celyad Oncology SA
GOSSELIES, Belgium and MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext...
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
August 05, 2022 01:00 ET
|
Celyad Oncology SA
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food...
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
August 01, 2022 01:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
July 28, 2022 01:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Leadership Updates
June 24, 2022 01:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
May 31, 2022 02:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 16:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 18:12 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 16:05 ET
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...